Get started
Author

Sara Rothschild

Observed name: Rothschild, Sara
Institution: Life Raft Group
ORCID: 0000-0001-6602-3924
Observed ORCID: 0000-0001-6602-3924
OpenAlex ID: A5023986803
Rethinking placebos: embracing synthetic control arms in clinical trials for rare tumors
2023 · César Serrano, Sara Rothschild, et al. · Nature Medicine · 29
Localized and diffuse tenosynovial giant cell tumor: real-world results from a patient observational registry
2025 · Sydney Stern, Patrick F. McKenzie, et al. · Future Oncology · 9
A Review of Genomic Testing and SDH ‐ Deficiency in Gastrointestinal Stromal Tumors: Getting to the GIST
2025 · Vaia Florou, Michelle F. Jacobs, et al. · Cancer Medicine · 9
PDF
Leveraging Patient Engagement Through Collaboration for Improved Global Health Outcomes in Sarcoma
2024 · Denisse Evans, Sara Rothschild, et al. · American Society of Clinical Oncology Educational Book · 4
PDF
Adjuvant Imatinib or Observation in Patients With Gastrointestinal Stromal Tumors With KIT Exon 9 Mutations
2026 · Andrea Napolitano, Heikki Joensuu, et al. · JAMA Oncology · 3
Pediatric patients with tenosynovial giant cell tumor: real-world evidence from an observational registry
2026 · Sydney Stern, Patrick F. McKenzie, et al. · Orphanet Journal of Rare Diseases · 1
Undetected KIT and PDGFRA mutations: an under-recognised cause of gastrointestinal stromal tumours (GISTs) incorrectly classified as wild-type
2022 · Annalisa Astolfi, Anthony Gill, et al. · Pathology · 1
PDF
Supplementary Table S5 from Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment
2026 · Homma M. Khosroyani, Alina Teuber, et al.
Supp. Fig. 2 from Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment
2026 · Homma M. Khosroyani, Alina Teuber, et al.
Figure 2 from Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment
2026 · Homma M. Khosroyani, Alina Teuber, et al.
Supplementary Table S4 from Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment
2026 · Homma M. Khosroyani, Alina Teuber, et al.
Supplementary Table S6 from Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment
2026 · Homma M. Khosroyani, Alina Teuber, et al.
Supplementary Table S2 from Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment
2026 · Homma M. Khosroyani, Alina Teuber, et al.
Supp. Fig. 6 from Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment
2026 · Homma M. Khosroyani, Alina Teuber, et al.
Figure 4 from Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment
2026 · Homma M. Khosroyani, Alina Teuber, et al.
Supplementary Table S7 from Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment
2026 · Homma M. Khosroyani, Alina Teuber, et al.
Supplementary Table S3 from Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment
2026 · Homma M. Khosroyani, Alina Teuber, et al.
Supp. Fig. 4 from Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment
2026 · Homma M. Khosroyani, Alina Teuber, et al.
Supp. Fig. 5 from Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment
2026 · Homma M. Khosroyani, Alina Teuber, et al.
Figure 1 from Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment
2026 · Homma M. Khosroyani, Alina Teuber, et al.
Supplementary Table S1 from Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment
2026 · Homma M. Khosroyani, Alina Teuber, et al.
Supp. Fig. 7 from Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment
2026 · Homma M. Khosroyani, Alina Teuber, et al.
Data from Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment
2026 · Homma M. Khosroyani, Alina Teuber, et al.
Figure 3 from Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment
2026 · Homma M. Khosroyani, Alina Teuber, et al.
Supp. Fig. 3 from Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment
2026 · Homma M. Khosroyani, Alina Teuber, et al.
Works count: 37
Citation count: 56
H-index: 4
I10-index: 1
Year
Topic
Type